1. Scrip
  2. >>Business

Lundbeck's Migraine Therapy Vyepti: Overcoming The COVID-19 Effect

Northera Suffers Generic Erosion In First Quarter

 
• By John Davis

Denmark’s Lundbeck is aiming to build up use of its latest neurological, the long-acting migraine preventative, Vyepti, now that US healthcare is emerging from COVID-19-related restrictions, but is facing headwinds from loss of exclusivity on Northera.

woman with migraine
Migraines can be debilitating • Source: Alamy

H. Lundbeck A/S’s new migraine preventive therapy, Vyepti (eptinezumab-jjmr), picked up sales momentum in the US in the first quarter of 2021, recovering the lost trajectory from launching at the start of the COVID-19 pandemic in 2020. And a second neurological product, the antidepressant, Brintellix/Trintellix (vortioxetine), is showing promise in patients with comorbidities of major depressive and generalized anxiety disorders, the company has reported. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.